Literature DB >> 16885722

Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.

Marilyn A Huestis1, Mahmoud Elsohly, Wesenyalsh Nebro, Allan Barnes, Richard A Gustafson, Michael L Smith.   

Abstract

Estimating the time of last cannabis use is important in assessing possible impairment of drivers involved in accidents, in verifying accuracy of court testimony and in the future, helpful in therapeutic monitoring of cannabis agonists. In 1992, Huestis et al developed model 1, based on plasma Delta-tetrahydrocannabinol (THC) concentrations, and model 2, on plasma 11-nor-9-carboxy-Delta(9)-tetrahydrocannbinol/THC ratios, that predicted 95% confidence intervals for time of last cannabis use. These models seemed to be valuable when applied to the small amount of data from published studies of oral ingestion, a route of administration more popular with the advent of cannabis therapies. A study was designed to further validate the models after oral ingestion of THC, and to determine whether they could predict last usage after multiple oral doses. Eighteen subjects in IRB-approved studies participated after providing informed consent. Each of 12 subjects in one group received a single 10 mg oral dose of dronabinol (synthetic THC). In another protocol, 6 subjects received 4 different oral daily doses, divided into thirds and administered with meals for 5 consecutive days. There was a 10-day washout period between each dosing regimen. Daily doses were 0.39, 0.47, and 14.8 mg THC in hemp oil and 7.5 mg dronabinol. Blood specimens were collected throughout the study and analyzed for plasma THC and 11-nor-9-carboxy-Delta(9)-tetrahydrocannbinol by gas chromatography/mass spectrometry with limits of quantification (LOQs) of 0.5 and 1.0 ng/mL, respectively. Actual times between ingestion of THC and blood collection spanned 0.5 to 16 hours. All plasma specimens with analyte concentrations >LOQ (n=90) were evaluated. Models 1 and 2 correctly predicted time of last THC ingestion for 74.4% and 90.0% of plasma specimens, respectively. 96.7% of predicted times were correct with one overestimate and 2 underestimates using the time interval defined by the lowest and highest 95% confidence limit of both models. These results provide further evidence of the usefulness of the predictive models in estimating the time of last oral THC ingestion after single or multiple doses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885722     DOI: 10.1097/00007691-200608000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  15 in total

1.  Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; William D Darwin; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

2.  Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

Authors:  Nicolas J Schlienz; Edward J Cone; Evan S Herrmann; Natalie A Lembeck; John M Mitchell; George E Bigelow; Ronald Flegel; Charles P LoDico; Eugene D Hayes; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2018-05-01       Impact factor: 3.367

3.  Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration.

Authors:  Cristina Sempio; Marilyn A Huestis; Susan K Mikulich-Gilbertson; Jost Klawitter; Uwe Christians; Thomas K Henthorn
Journal:  Br J Clin Pharmacol       Date:  2020-01-20       Impact factor: 4.335

Review 4.  Bioanalytical procedures for monitoring in utero drug exposure.

Authors:  Teresa Gray; Marilyn Huestis
Journal:  Anal Bioanal Chem       Date:  2007-03-17       Impact factor: 4.142

5.  Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).

Authors:  Michael G Holland; David M Schwope; Robert Stoppacher; Shane B Gillen; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2011-07-20       Impact factor: 2.395

6.  Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.

Authors:  Erin L Karschner; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-03-29       Impact factor: 4.492

Review 7.  Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.

Authors:  Kathleen M Carroll; Brian D Kiluk; Charla Nich; Elise E DeVito; Suzanne Decker; Donna LaPaglia; Dianne Duffey; Theresa A Babuscio; Samuel A Ball
Journal:  Drug Alcohol Depend       Date:  2014-01-31       Impact factor: 4.492

8.  Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

Authors:  Garry Milman; Allan J Barnes; Ross H Lowe; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2010-01-04       Impact factor: 4.759

9.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

10.  Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Authors:  Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.